Comanche Biopharma is a biopharmaceutical company focused on developing an investigational small interfering RNA (siRNA) medicine aimed at treating preterm preeclampsia. The company is committed to ensuring that all women and their babies have access to safe and effective therapies for life-threatening complications during pregnancy. Comanche Biopharma's mission emphasizes the importance of evidence-based and affordable solutions, enabling women to receive cost-effective treatments that address the root causes of preeclampsia.
Latchel provides an operations platform intended to track maintenance and vendor selection. The company's platform provides maintenance tracking and vendor selection services by property management companies to track maintenance requests, increase net margins, and increase renter satisfaction via mobile application, enabling users to connect automatically with the tenants. Latchel was founded on 2016 and is based in Seattle, Washington.
Spry is a digital health platform that enables movement health professionals to collect and analyze patient data in real time. By leveraging machine learning and artificial intelligence, the platform provides personalized protocols based on evidence-based practices and standards of care. This allows practitioners and owners of physical therapy centers to effectively manage both clinical and administrative functions, enhancing the quality of patient care and operational efficiency.
Immuneel Therapeutics specializes in developing innovative cell and gene therapies for cancer treatment. The company focuses on CAR-T cell therapies, which are created by extracting blood cells from patients and genetically engineering healthy immune cells to specifically target malignant cells. This approach allows cancer patients to benefit from advanced cell-based immunotherapies that have the potential to transform their treatment outcomes.
We are the first in class pre-clinical translational biophysics company focusing on the discovery of novel therapeutics against intrinsically disordered targets.
CHARM Therapeutics delivers transformational medicines through 3D deep learning and cutting-edge drug discovery technologies. It delivers transformational medicines through 3D deep learning and cutting-edge drug discovery technologies to help doctors in treating undruggable disease targets.
Teleo specializes in converting existing fleet into supervised autonomous robots. It enables operators to control machines from miles away, instantly switching between machines and across job sites. Teleo increases the operator's productivity, enhances crew safety, and features advanced Jobsite insights.
Proof Diagnostics is a life sciences tools, diagnostics, and computational discovery company that develops both therapeutic and diagnostics applications while developing a smart, portable system for the detection of infectious and other diseases.
Doceree is a healthcare marketing technology company. They specialize in providing a platform and solutions for pharmaceutical and healthcare brands to connect with healthcare professionals (HCPs). Doceree's platform may include features like targeted advertising, data analytics, and tools to help pharmaceutical companies and healthcare brands effectively reach and engage with healthcare professionals in a compliant and efficient manner.
AmplifyMD is a telemedicine platform that connects over 3,300 medical institutions, particularly in rural and underserved areas, with a network of specialists. By offering a customized telehealthcare system, AmplifyMD enables hospitals to access on-demand specialists remotely, facilitating specialty coverage through virtual care. The platform not only streamlines clinical workflows but also automates billing processes, integrating smoothly with existing electronic health records (EHRs). This service helps hospitals minimize unnecessary patient transfers and reduces the need for costly locum tenens, ultimately improving patient care and operational efficiency.
Aerium Therapeutics is discovering and developing novel monoclonal antibodies (mAbs) and antiviral treatments against SARS-CoV-2 variants.
Mathison is the first all-inclusive technology for diversity hiring and retention. Our platform delivers top-of-funnel diversity sourcing, a system to reduce bias in the hiring process, and tools to mobilize the entire team around diversity hiring efforts. Mathison is leveraged by leading brands from Accenture, Sonos and TripAdvisor to 23andMe and HelloFresh.
SKUteam founded in 2020: a transformational year for global businesses amidst a global pandemic, by a group of early former Flexport executives We power global manufacturing with local expertise, starting with the apparel and home furnishing industries, delivering in-line intelligence, online. From Tech Pack Tune Ups, Sampling, Production Monitoring to Quality Assistance, we got you covered with on-site monitoring.
Rialtic operates an open marketplace enterprise platform designed to equip and assist payers to make accurate healthcare payments. The company's platform provides a reference source repository, curated material, and payment accuracy technology, allowing users to minimize the total cost of payment accuracy, keep up with changes more easily, and invent new concepts.
Canary Technologies is an enterprise hospitality technology company that provides hotels with innovative solutions to drive efficiency and enhance the guest experience. The company's core solutions get rid of antiquated technology in hotels. With backing from some of the top investors in Silicon Valley, Canary Technologies is trusted by thousands worldwide and serves some of the world’s largest and most iconic hotel brands.
Expressable is an online speech therapy practice for everyone with a communication disorder. It has pioneered a parent-focused care model that uses technology and education to integrate speech therapy techniques into children's daily lives, improving outcomes and experiences.
Parrot Software offers the most innovative and best software, hardware, and process consulting solutions for point of sale and satellite optimization satisfaction of our restaurant and/or fast-food customers. The software handles all of the expected tasks, including customer payments, ordering, seating, and data visualization.
K36 Therapeutics translate epigenetic modulation of oncogenic pathways into small molecule therapies.
AviadoBio is focused on developing innovative gene therapies aimed at transforming the lives of individuals affected by neurodegenerative disorders, specifically frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company leverages advanced research from King's College London and the UK Dementia Research Institute to create its therapeutic platform. By integrating a comprehensive understanding of brain biology with proprietary gene therapy techniques, AviadoBio seeks to address the challenges of effectively delivering treatments to targeted areas in the brain. This approach aims to enhance the therapeutic potential of gene therapies, offering hope for halting or potentially reversing the progression of these debilitating diseases.
Notabene helps financial companies comply with new, global regulations for crypto transactions. We are the first platform that provides full compliance with the Travel Rule. Our current offering consists of a unified API and dashboard helping compliance officers within crypto businesses manage risk for both Travel Rule and non-custodial transactions. We provide our customers with access to the widest reach of crypto businesses for them to interact with. We not only simplify compliance for them but also bring more confidence to transactions on their platforms - ultimately helping them grow the number of transactions and thus their business.
Hone is a live learning platform for management training that cultivates soft skills with hard data. Hone blends the best of expert-led small group training, peer learning, continuous reinforcement, and a technology platform to develop better leaders, managers, and teammates for today’s workplace. The company's platform helps to expand, connect, and let leaders analyze the impact of the training on the organization to provide improvement for team development. Hone was established in 2018 by Tom Griffiths and Savina Perez in Encinitas, California.
Patina is a healthcare provider focused on enhancing the aging experience for older adults and their families. The company has developed a care model that prioritizes the unique needs and values of this demographic. By offering personalized and on-demand services, Patina aims to create a healthcare experience that is both human-centered and supportive. This approach allows families to actively participate in the care of their loved ones, ensuring that older adults receive the attention and respect they deserve as they navigate the challenges of aging. Patina's mission is to empower individuals to live their best lives and maintain their dignity as they age.
Neumora Therapeutics is a clinical-stage biotechnology company focused on developing precision medicines for brain diseases by combining data science with neuroscience. Founded to address the global brain disease crisis, Neumora takes an innovative approach to treatment development. The company has established a robust therapeutic pipeline that includes seven clinical and preclinical neuroscience programs targeting novel mechanisms of action for various underserved neuropsychiatric and neurodegenerative disorders. Neumora plans to advance its pipeline further by initiating multiple clinical trials across its programs in the upcoming 12 to 18 months.
Burro is a mobile application for Android and iOS devices that offers delivery and on-demand moving services to its users. The application enables its users to request pickups by filling up their personal information and items required. The platform offers its services to individuals and businesses. Its delivery portfolio consists of household goods, carpets, wood, and retail store items. Burro was launched in 2014 by Jason Ervin and Ethan Hurtado and is based in Texas.
Burro is a developer of an autonomous farming platform for farm use and in other outdoor environments. It follows people and can autonomously run cargo around, relieving people of strenuous tasks which add little value, so that they can focus on more valuable work.
Adela develops innovative and accessible technologies focusing on the detection of cancer and other high-morbidity, high-mortality conditions through a routine blood test. Adela’s genome-wide methylome enrichment platform captures information efficiently from the entire methylome. Its technology distinguishes the most-highly informative (methylated) regions of the genome from non-informative regions and preferentially targets those regions for sequencing.
Zus Health helps a new wave of healthcare builders create technologies and services without the usual blockers. Zus Health aims to bring forth a better health reality by empowering an inspired new wave of healthcare builders to create digital technologies and services that are cheaper, easier to customize, and far more intimate. Zus Health was established in 2020 in Watertown, Massachusetts by Jonathan Bush.
Pediatrix Therapeutics is a pharmaceutical company focused on the field of pediatrics by developing and introducing effective and clinically proven children's medicines to provide Chinese children and families with high-quality and affordable treatment options.
Logixboard is a white-labeled customer experience software that helps logistics service providers increase sales and retain customers. It connects directly to your internal software and can be launched in less than three weeks with very little effort from your team.
Leyden Labs is focused on developing intranasal products that aim to protect individuals from respiratory viruses, including those in the influenza and coronavirus families. The company's innovative approach targets common characteristics across various viral families, allowing for simultaneous protection against multiple viruses rather than just specific variants, as is the case with traditional vaccines. This strategy seeks to empower individuals to safeguard themselves from infections and reduce the transmission of these diseases. Leyden Labs is driven by a team of experienced biotechnology professionals who are committed to advancing solutions that alleviate the impact of respiratory viruses on public health.
AppliedVR offers virtual reality-based treatments that address the complexity of chronic pain. The company's mission is to empower patients with the tools to live life, beyond chronic pain. Rooted in cognitive behavioral therapy and mindfulness, AppliedVR’s EaseVRx is the first VR-based prescription therapeutic to receive Breakthrough Device Designation by the FDA. Offering a comprehensive approach that encompasses the biological, psychological and social factors that influence how people experience chronic pain, EaseVRx enables patients to change the way they process pain and develop new, positive habits and coping skills that improve quality of life. Patients can easily self-administer EaseVRx in the comfort of their own homes, at any time, without restrictions tied to a healthcare professional’s schedule — advancing remote care as well as quality, equity and efficiency in chronic pain management.
Vendr is a SaaS buying and management platform that helps companies find the right software, buy it at a fair price, and manage it effortlessly. As the SaaS buying category creator with the largest data set, Finance and Procurement teams have the ability to tap into Vendr for any part of the purchasing process, from searching for new tools to negotiating back and forth, to catching up on upcoming renewals. The company was founded in 2019 and is based in Boston, Massachusetts. Recently raised $150M Series B and acquired SaaS management platform, Blissfully, to expand our capabilities for our customers.
Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As a result, Ensoma’s therapies can be delivered as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited.
Equip is a virtual program helping families recover from eating disorders at home with comprehensive, gold-standard care created by experts in the field and people in recovery. Equip’s five-person care teams include dieticians, physicians, therapists, and mentors who deliver wrap-around support to provide families progress and lasting recovery. Kristina Saffran and Erin Parks co-founded the company in San Diego, California in 2019.
Equip is a virtual program helping families recover from eating disorders at home with comprehensive, gold-standard care created by experts in the field and people in recovery. Equip’s five-person care teams include dieticians, physicians, therapists, and mentors who deliver wrap-around support to provide families progress and lasting recovery. Kristina Saffran and Erin Parks co-founded the company in San Diego, California in 2019.
ConnexPay transforms payment acceptance and issuance for Travel and E-commerce providers which act as intermediaries. By offering clients a revolutionary way to minimize risks and reduce credit and debit card acceptance costs through linked real-time payments issued to suppliers, ConnexPay’s clients avoid the need for large lines of credit or personal guarantees. ConnexPay provides a comprehensive, integrated payments solution which incorporates powerful anti-fraud detection along with PCI-certified payment acceptance and payment issuance — driven by ConnexPay’s patent pending intelligent routing and single-use virtual cards — to handle every step of the process. Through a single provider under a simple contract, Travel and E-commerce providers can accept payments from clients and issue payments to suppliers with single-use virtual cards from multiple major card brands. ConnexPay’s advanced solution does not require clients to obtain large lines of credit, provide large reserves, or prepay for most services. Their difference makes all the difference.
Argyle is the developer of a payroll connectivity platform for providing modern financial services. The company's platform enables businesses to automate verifications and background checks, fund accounts, switch direct deposits, compute premiums, advance wages, and perform other functions.
Citrine Medicine is a rare disease-focused pharmaceutical firm.
Sana Biotechnology focuses on creating and delivering engineered cells as medicine for patients. Recent scientific advances make it possible to reprogram cells in the body or replace damaged cells and tissues, creating a new class of medicines to treat a broad array of diseases. The company is a team of scientists, clinicians and biotechnology veterans focused on creating an enduring company that makes meaningful medicines and will change the approach in treating diseases.
NFlection Therapeutics is a biopharmaceutical company focusing on targeted treatments for rare diseases. It primarily addresses the needs of patients with neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks such as keratinocytic epidermal nevi and nevus sebaceous.
Arvelle Therapeutics is a biopharmaceutical company with the mission of bringing innovative solutions to patients suffering from CNS disorders.
Owkin is a French-American startup that uses artificial intelligence to find the right treatment for every patient. Our focus is to use AI to discover and develop better treatments for unmet medical needs, starting with the fight against cancer. They use AI to identify new drug candidates, de-risk and accelerate clinical trials and build diagnostic tools that improve patient outcomes. Using federated learning, a pioneering collaborative AI framework, Owkin enables medical and biopharma partners to unlock valuable insights from siloed datasets, while protecting patient privacy and securing proprietary data. Owkin was co-founded by Thomas Clozel MD, a clinical research doctor and former assistant professor in clinical onco-hematology, and Gilles Wainrib, a pioneer in the field of machine learning in biology, in 2016. Owkin has raised over $255 million and became a ‘unicorn’ – a startup valued at more than $1 billion – in November 2021 through a $180 million investment from French biopharma company Sanofi.
Affinia Therapeutics is a developer of a platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies intended to develop medicines for devastating diseases. The company leverages synthetic and systems biology combined with high-throughput screening and tissue and single-cell resolution for people affected by muscle and central nervous system (CNS) diseases with significant unmet needs, thereby providing medical professionals with the rational design of novel vectors and gene therapies with remarkably improved properties.
Prime Medicine is a biotechnology company founded to deliver on the promise of Prime Editing, a versatile gene editing technology that can truly "search and replace" to restore normal genetic function and address the fundamental causes of disease.
AvantStay is the premier next generation hospitality platform. We are redefining the way in which people travel, transact and invest. AvantStay assures a highly-curated experience customized to guests’ needs, using a proprietary tech suite to power bookings, seamlessly operationalize in-field and remote management, and activate authentic and elevated consumer touch points. AvantStay currently operates in over 60 cities, with a drive-to market approach, including 450+ premier properties across their diversified portfolio, and an AUM of more than $800M. In 2019, AvantStay became one of the initial twelve partners of Homes & Villas by Marriott International, and currently offers direct bookings on more than 50 OTAs.
Firefly Health provides primary health care services that redefine high-quality patient care. The company uses sophisticated technology with a thoughtful care team experience for continuous, intelligent care that changes behavior and drives value by providing virtual-first primary care approach, live video appointments with primary care physician and team for convenience without any membership fees, allowing people to make smart choices about their health, while enabling clinicians to provide unparalleled, consistent, and proactive care.
Nocion Therapeutics is a developer of novel pharmaceuticals intended to treat the conditions arising from neurogenic inflammation. The company is developing "nocions" which are a new kind of therapy that selectively affects actively firing nociceptors, enabling patients to provide targeted, robust and sustained relief for the treatment of serious conditions including cough, itch, pain and inflammation.
Embark offers dog DNA testing that ends preventable diseases in dogs. It was founded by top experts in genomics, computational biology, and software design to sell an industry-leading dog DNA test. They use a clinical-grade CLIA-certified SNP chip to provide the most accurate and comprehensive results (200,000+ genetic markers) available on the market. Their data contributes to proprietary genetics research that will help dog owners optimize nutrition, exercise, allergies, and prevent a variety of heritable conditions. Their technological advantage, intellectual capital, and research-focus enable them to push canine health toward our shared vision of preventative veterinary care.
Structure Therapeutics creates life-changing medicines for patients using advanced computational and structure-based technology. Our platform combines the latest advancements in computational chemistry, visualization of molecular interactions, and data integration to design orally available, superior medicines that overcome current limitations in biologic and peptide drugs. We are advancing our clinical-stage pipeline of differentiated, efficacious and safe treatments focused on chronic diseases with high unmet need, including cardiovascular, metabolic and pulmonary conditions. At Structure, our team’s deep experience with complex biological targets and mechanisms, structure-based drug design, and global drug discovery and development enables our bold vision: to design and develop world-class medicines with tremendous patient impact and broad commercial opportunity.
Owkin is a French-American startup that uses artificial intelligence to find the right treatment for every patient. Our focus is to use AI to discover and develop better treatments for unmet medical needs, starting with the fight against cancer. They use AI to identify new drug candidates, de-risk and accelerate clinical trials and build diagnostic tools that improve patient outcomes. Using federated learning, a pioneering collaborative AI framework, Owkin enables medical and biopharma partners to unlock valuable insights from siloed datasets, while protecting patient privacy and securing proprietary data. Owkin was co-founded by Thomas Clozel MD, a clinical research doctor and former assistant professor in clinical onco-hematology, and Gilles Wainrib, a pioneer in the field of machine learning in biology, in 2016. Owkin has raised over $255 million and became a ‘unicorn’ – a startup valued at more than $1 billion – in November 2021 through a $180 million investment from French biopharma company Sanofi.
Renshu Medical is an otolaryngology specialist chain covering areas such as suppurative otitis media, allergic rhinitis, chronic sinusitis and thyroid cancer. It provides users with Danish ear hearing detection, nasal endoscopy video examination and nasopharyngoscopy, specialists test report interpretation and other services; and can use WeChat appointment appointment time, appointment hospital experts.
Castle manages rental homes for landlords using automation and on-demand labor. It finds tenants, collect rent, and coordinate maintenance, allowing owners to kick back, relax, and never worry about their rental properties again. Owners either have to deal with this whole mess themselves, or spend 10% of their rental income on a traditional property management company that requires constant supervision and is often incentivized to act against the owner’s best interest. There are 43 million rental units in the United States, and most of them are currently managed with some combination of faxes, mail, and unreturned voicemails on the landlord’s personal phone. Castle moves all of property management into a seamless online experience, providing owners with transparency, speed, and incredible customer service—plus huge cost savings over traditional management. Renters get great service and instant updates about important issues.
Castle provides an identity platform that helps online businesses detect and prevent user account fraud, a capability previously accessible mainly to banks and large financial institutions. The company offers APIs that enable various customer-facing applications, such as e-commerce sites and mobile apps, to implement account hijack protection. Castle employs real-time security analytics to monitor user behavior, tracking indicators like device fingerprints, keystrokes, and browsing history. When suspicious activity is detected, both administrators and account owners receive alerts, allowing for immediate corrective action. By centralizing data analysis and decision-making, Castle effectively combats automated credential stuffing attacks and uncovers sophisticated fraud rings, enhancing the protection of users' account information.
Geneception
Series A in 2019
Geneception is a company focused on the development of breakthrough in gene and cell therapies that are fully-integrated.
Innovusion is a leading developer of image grade LiDAR sensor systems for the level 4 and 5 of the autonomous vehicle and ADAS markets. Their unique combination of range, resolution, hardware-accelerated sensor fusion, compact size, ease of integration, and cost-effectiveness makes our products the ideal choice for the most demanding applications. We are venture-backed and headquartered in the heart of Silicon Valley.
Nebula Genomics is a human genome sequencing and health big data company on a mission to usher in the era of genomic sequencing by building a large and trusted genomic and health data marketplace for consumers, researchers and the medical community. Using blockchain to ensure that consumers maintain control of their data and are compensated for its use, the Nebula marketplace will aggregate a critical mass of rich genetic information that researchers can analyze in order to accelerate drug development, streamline clinical trials, and usher in the era of truly personalized medicine. The company was founded by Harvard genomics pioneer George Church, along with Harvard researchers Dennis Grishin and Kamal Obbad. Founded in 2017, Nebula Genomics has offices in San Francisco, CA and Boston, MA and is backed by investors including Khosla Ventures, Arch Venture Partners, Fenbushi Capital, Mayfield, F-Prime Capital Partners, GreatPoint Ventures, Hemi Ventures and Mirae Asset.
Modis Therapeutics is bringing disease-modifying therapies to patients with rare genetic diseases.
Xilio Therapeutics is a biotechnology company. They offer cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. Their tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects.
B-One Ortho Corp. is a manufacturer of orthopedic healthcare solutions, specializing in artificial joints that facilitate joint replacement surgeries. Founded in 2015 and headquartered in Cedar Knolls, New Jersey, the company also maintains offices in Shanghai and Suzhou, China. Its notable products include the B-One total hip system, which features advanced coating technology and instrumentation, as well as the Juveno bone-conserving femoral prosthesis and primary acetabular systems. These innovations aim to enhance the effectiveness of hip and knee arthroplasty, ultimately helping patients regain their mobility and improve their quality of life.
Notable is the AI platform for healthcare operations. Deployed at over 10,000 sites of care, Notable automates over a million repetitive workflows every day across Registration and Intake, Scheduling and Referrals, Assistant, Authorizations, Care Gap Closure, and HCC Chart Review. The result: personalized, streamlined care for patients, the elimination of burdensome manual work for caregivers, and improved financial health for healthcare providers.
AvantStay is the premier next generation hospitality platform. We are redefining the way in which people travel, transact and invest. AvantStay assures a highly-curated experience customized to guests’ needs, using a proprietary tech suite to power bookings, seamlessly operationalize in-field and remote management, and activate authentic and elevated consumer touch points. AvantStay currently operates in over 60 cities, with a drive-to market approach, including 450+ premier properties across their diversified portfolio, and an AUM of more than $800M. In 2019, AvantStay became one of the initial twelve partners of Homes & Villas by Marriott International, and currently offers direct bookings on more than 50 OTAs.
Metcela is a clinical-stage biotech startup providing patients with an innovative and alternative treatment option for heart disease. The company's lead asset, MTC001 is a cell therapy based on VCAM-1-positive Cardiac Fibroblast (VCF) that re-established a favorable microenvironment and repaired damaged heart tissues in preclinical studies. Metcela's therapy uses a specific fibroblast cell that is obtained from the patient's heart and instead of replacing them, it repairs the damage by enhancing the cells' ability to heal, providing patients with an effective and reasonably-priced cure for heart failure. It was founded on March 9, 2016, and is headquartered in Kawasaki, Japan.
Engine by MoneyLion provides embedded finance and marketplace platforms for financial services. The company offers a range of services, including a search, comparison, and recommendation engine for financial products and a suite of tools for offer management and optimization. Its services enable businesses to add financial products to their operations, providing personalized financial product offers to clients. It was formerly known as Even Financial.
CareStack is a single all-in-one platform on the cloud that combines dental practice management, patient engagement, practice marketing, and data analytics. CareStack is currently used by large and growing practices as an all-in-one solution to increase productivity, minimize costs, and improve patient dental care. CareStack's mission is to help dentists to have a better practice and a better life. Through their technology-led offerings, CareStack will elevate dental offices to a higher degree of financial success.
Centivo is a new type of health plan administrator that allows self-funded employers and clinicians to join forces and deliver high quality, affordable healthcare to their employees. An alternative to traditional insurance carriers or third-party administrators, Centivo offers the technology, network, claims processing, customer support, and population health management to fully administer health benefits for all or a portion of an employee population. The Centivo model emphasizes the partnership between individuals and their primary care team as the proper model to coordinate healthcare needs. Centivo’s clinical partners are dedicated to controlling costs and helping members navigate the healthcare system, aided by personalized patient/doctor matching tools. Members are rewarded for working with their primary care team and choosing high-value care and are supported through a user-friendly app and their concierge. Employers get an ally that diligently roots out waste and is accountable for performance. It was formed in 2017 and headquartered in New York, United States.
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, developing antibody therapeutics to treat both solid tumors and hematologic malignancies. Compass is leveraging its proprietary StitchMabs™ and common light-chain enabled multispecific platforms to empirically identify multispecifics and combinations of antibody therapeutics that can be advanced to the clinic. The company's lead product candidate, CTX-009, is a bispecific antibody, which inhibits both DLL4-mediated Notch signaling and VEGF-A signaling. CTX-009 has completed a Phase 1 dose escalation study and is in a Phase 1b study in combination with chemotherapy in patients with solid tumors. The company’s second product candidate, CTX-471, is a novel agonistic antibody of CD137, a co-stimulatory receptor on immune cells. It is currently being evaluated in a Phase 1b study in patients who were previously treated with PD-1/PD-L1 checkpoint inhibitors, and who subsequently relapsed or progressed after a period of stable disease. Compass’ third product candidate, CTX-8371, is a bispecific antibody that blocks both PD-1 and PD-L1 and is in IND-enabling studies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
NodThera is a Cambridge (UK) headquartered biotech engaged in innate immune/ inflammasome research. Their leading project is focused on developing inhibitors of the NLRP3 inflammasome for the treatment of inflammatory and neuroinflammatory diseases.
Beam Therapeutics is a biotechnology company engaged in creating genetic medicines based on its base editing technology. It is pioneering the use of base editing, a potential new class of precision genetic medicines, with a vision of providing life-long cures to patients suffering from serious diseases. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the dna.
Zenflow, Inc. is a medical device company based in San Francisco, California, that specializes in providing innovative solutions for men suffering from benign prostatic hyperplasia (BPH) symptoms. Founded in 2014 by a team of Stanford University Biodesign Fellows in collaboration with leading urologists, the company aims to address the significant unmet clinical need for effective urinary obstruction treatments. Zenflow's primary product is a spring-like device designed to gently prop open the urethra, restoring its normal function without damaging surrounding tissues. This approach prioritizes patient comfort and minimizes invasiveness, offering a less painful alternative to traditional treatments for urinary obstruction caused by an enlarged prostate.
Lighthouse is a commercial platform for the travel & hospitality industry. The company transforms complexity into confidence by providing actionable market insights, business intelligence, and pricing tools that maximize revenue growth. Lighthouse was previously known as OTA Insight.
Oviva is digitizing the treatment of type 2 diabetes and obesity through a unique behavior change platform. They have developed unique, personalised behaviour change programmes that combine smartphone app and learning portals to support dietitian-led behaviour change for conditions such as type 2 diabetes and complex obesity. Their approach allows patients to achieve a better health outcome without having to attend clinic appointments, whilst saving health systems significant sums by preventing the development of complications related to these health conditions. Oviva was founded in 2013 and is based in London, England.
Optimus Ride is a self-driving vehicle company based in Boston, MA. It designs technologies to enable efficient, sustainable, and equitable mobility systems and solutions. As an MIT spinoff company, it combines over 30 years of interdisciplinary university research in self‑driving technologies (DARPA Urban Challenge), electric vehicles (CityCar), and Mobility-on-Demand Systems. The team includes decades of industrial and entrepreneurial experience that combines manufacturing robots, urban design, and shared vehicle fleet management.
Devoted Health is an all-in-one healthcare company on a mission to dramatically improve the health and well-being of older Americans by caring for every person like family. To accomplish this, Devoted Health has designed and built an integrated healthcare solution that combines Devoted Health Medicare Advantage plans, access to top local providers alongside virtual and in-home care delivered by Devoted Medical, full-service guides, and world-class technology that powers it all.
Vestwell develops a digital savings platform to create a retirement plan for employees. It offers automated retirement investing options for RIAs depending on the rules and regulations and other defined contributions to companies and their employees to help advisers engage with their clients with compliance and automation.
Buoy provides a personalized all-in-one platform to help guide consumers back to health. Whether it's chatting about symptoms with Buoy Assistant to get help in the moment of sickness or researching benefits through Buoy Dashboard, Buoy is available 24/7 to help make self-diagnosis and navigating the healthcare system simple and easy. For employers, Buoy can be custom configured to surface benefits information and wellness programs, guide employees to in-network providers, and fully integrate with other health portals. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Protenus harnesses the power of AI to provide healthcare organizations with scalable risk-reduction solutions that drive the safest patient outcomes while protecting the reputation of the organizations. We are committed to innovation, determined to reduce risk, and focused on supporting our community of employees, customers, and ultimately, patients. Empowering healthcare to eliminate risk is at the heart of all we do. Founded in 2014, Protenus is a three-time winner of Forbes’ America’s Best Startup Employers, is a Great Place to Work®-Certified company, and was named one of 2021 CBInsights Digital Health 150, one of The Best Places to Work in Healthcare by Modern Healthcare, and one of the Best Places to Work in Baltimore by the Baltimore Business Journal and the Baltimore Sun. Learn more at Protenus.com and follow us on Twitter @Protenus.
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, developing antibody therapeutics to treat both solid tumors and hematologic malignancies. Compass is leveraging its proprietary StitchMabs™ and common light-chain enabled multispecific platforms to empirically identify multispecifics and combinations of antibody therapeutics that can be advanced to the clinic. The company's lead product candidate, CTX-009, is a bispecific antibody, which inhibits both DLL4-mediated Notch signaling and VEGF-A signaling. CTX-009 has completed a Phase 1 dose escalation study and is in a Phase 1b study in combination with chemotherapy in patients with solid tumors. The company’s second product candidate, CTX-471, is a novel agonistic antibody of CD137, a co-stimulatory receptor on immune cells. It is currently being evaluated in a Phase 1b study in patients who were previously treated with PD-1/PD-L1 checkpoint inhibitors, and who subsequently relapsed or progressed after a period of stable disease. Compass’ third product candidate, CTX-8371, is a bispecific antibody that blocks both PD-1 and PD-L1 and is in IND-enabling studies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
RiskRecon Inc. is a software company that specializes in third-party risk management by offering vendor security assessments. Founded in 2011 and based in Salt Lake City, Utah, RiskRecon provides a cloud-based platform that delivers continuous monitoring and on-demand assessments of organizations' security practices. The platform analyzes third-party internet infrastructure and application presence, enabling users to objectively measure the quality of their security programs. By offering risk-prioritized action plans tailored to individual risk priorities, RiskRecon helps organizations effectively control third-party risks and improve accountability among stakeholders, ultimately leading to better risk management outcomes.
Biopalette is a operator of a platform intended to offer gene-editing techniques. Bio Palette plans to develop our business in three fields, classified based on the type of cells targeted for genome editing.
Blispay provides a streamlined in-store financing experience in the market. The Blispay Visa Card is a mobile-centric credit card in the industry, allowing merchants of all sizes to provide financing without any technical integration or financial obligation while customers get to enjoy instant issuance, 6-month special financing & 2% Cash Back. The company's first product is an everyday credit and financing solution that customers deserve and merchants need. Its founding team consists of experienced industry veterans from companies including BIll Me Later, PayPal, Bank of America, MBNA, Microsoft & Zynga.
Genoa Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of idiopathic pulmonary fibrosis (IPF). It develops GP-101, an aerosol pirfenidone formulation for direct inhalation delivery to the lungs for the treatment of IPF. The company was founded in 2011 and is based in San Diego, California.
Whatfix offers a digital adoption platform, simulated application environments for training, and no-code application analytics. Using GenAI supports companies in improving user productivity, ensuring process compliance, and improving user experience across internal and customer-facing applications.
At WelbeHealth, we envision a world in which every human being is able to participate fully in life through their final days. We serve frail seniors through a model of comprehensive medical and social care called PACE (Program of All-Inclusive Care for the Elderly), helping our participants live better, longer, and more independently. Founded by a seasoned group of physician entrepreneurs, our leadership team hails from leading payer and provider organizations such as GoHealth Urgent Care, BAYADA Home Health, AirStrip Technologies, Evolent Health, and On Lok. With funding from leading venture capital firms, we're looking for team members who are inspired to help us deliver on our mission of unlocking the full potential of the most vulnerable seniors in our communities. Our colleagues are energized by working in diverse groups toward our shared purpose, are eager to drive groundbreaking innovations, and have the courage to care for our participants with empathy and love.
Avalyn Pharma is a biopharma company that advances therapies for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other severe respiratory diseases. Its therapies rapidly advance AP01 for the treatment of IPF, provides additional pipeline candidates for IPF, improve the care and outcomes of severe respiratory diseases, and develop novel inhaled therapeutics. Avalyn Pharma was established in 2011 and is headquartered in Seattle, Washington.
Axoni is a real-time data replication technology company serving the world’s largest financial institutions. Axoni’s platform enables rapid, reliable deployment of critical financial networks and automated, real-time data replication across market participants. Founded in 2017, the company serves banks, asset managers, hedge funds, and financial market infrastructure firms across the globe from offices in New York and London.
Xilio Therapeutics is a biotechnology company. They offer cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. Their tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects.
Codeship's continuous integration platform operates B2D portal that delivers hosted continuous integration and deployment for web applications. It shortens the development cycles thus reducing the risk of bugs and increasing innovation. It helps software companies to develop a better product faster by taking care of the testing and release process. Codeship automates software deployment and all the necessary tasks involved with it.
Orchard Therapeutics is a fully integrated commercial-stage company dedicated to treating the lives of patients with rare diseases through innovative gene therapies. Orchard’s portfolio of autologous ex vivo gene therapy programs has demonstrated sustained clinical benefit in over 150 patients across five disease areas. These programs include Strimvelis®, the first autologous ex vivo gene therapy approved by the EMA in 2016, 3 programs in advanced registrational studies in MLD (metachromatic leukodystrophy), WAS (Wiskott-Aldrich syndrome), and ADA-SCID (adenosine deaminase severe combined immunodeficiency), 2 other clinical programs in X-CGD (X-linked chronic granulomatous disease) and beta-thalassemia, as well as an extensive preclinical pipeline. The company is partnered with world-leading institutions in gene therapy, including University College London, Great Ormond Street Hospital, the University of Manchester and Central Manchester University Hospitals, the University of California Los Angeles and Boston Children’s Hospital, and Telethon Institute of Gene Therapy/Ospedale San Raffaele.
Cytek Biosciences is a manufacturer and supplier of flow cytometry products and services.
Haiui Health Technology is a mobile platform for hospitals to connect patients, optimise hospital visits and streamline admin workflow.
PatientPing is a health technology company that is building a national network of engaged providers who are sharing information, coordinating care, and working together to get patients healthier faster. PatientPing connects healthcare providers across the country with real-time notifications and care guidelines whenever and wherever their patients receive care. PatientPing's national care coordination network includes physicians, nurses, case managers, and care coordinators across hospitals, emergency departments, accountable care organizations (ACOs), physician practices, skilled nursing facilities, home health agencies, inpatient rehabilitation centers, and payers. By connecting care teams through real-time information sharing, PatientPing enables providers to deliver higher quality and more cost-effective care, improving patient outcomes, and experience.
Leveraging a powerful combination of Healthcare delivery expertise, smart technology and stringent processes, we make Healthcare more accessible, accountable, accurate, and personal.
VitalWare is a leading mid-revenue cycle SaaS solutions provider specializing in Health-IT applications aimed at making the business of healthcare easier through its intuitive cloud-based technologies and regulatory content expertise. With over 590 healthcare institutions on its client roster, VitalWare’s product portfolio is the healthcare industry’s best solution for providing visibility and continuity in Chargemaster management, documentation, charge capture, and regulatory code references. Beyond providing tools and healthcare regulatory and compliance resources, VitalWare offers professional services designed to support providers in need of coding guidance, process improvement, education and financial impact solutions. VitalWare’s offerings are essential to client-partners in their efforts to provide appropriate reimbursement and continuous improvement.
Stride Health is a provider of an insurance recommendation platform designed to offer health insurance services. Everyone deserves a smart way to protect your health – and your wallet – without breaking a sweat. That’s why we do the tricky calculus for you. In minutes we’ll enroll you in your most cost-effective health plan, minimize your taxes and maximize your take-home pay as an independent worker or part-time employee. If that wasn’t enough, our personal advisors will navigate the details for you whenever you need us!
Denali Therapeutics Inc. is a biotechnology company based in South San Francisco, California, focused on developing therapies for neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). The company is advancing several therapeutic candidates, including LRRK2 inhibitors like DNL201 and DNL151 for Parkinson’s disease, and DNL747, a selective RIPK1 inhibitor currently in Phase 1b clinical trials for Alzheimer’s disease and ALS. Denali also develops various antibody and enzyme transport vehicles aimed at addressing the underlying biological mechanisms of neurodegenerative disorders. In addition to its internal programs, Denali has established collaborations with multiple organizations, including Takeda Pharmaceutical Company and Genentech, to enhance its research efforts. Founded in 2013, Denali Therapeutics leverages recent scientific advances to drive its mission of creating effective treatments for patients suffering from these challenging conditions.
Precision BioSciences is a biotechnology company dedicated to improving lives through its next-generation gene editing technology, ARCUS. Precision BioSciences’ mission is to translate the world’s most powerful genome editing technology into greatly needed products throughout the life sciences. Precision’s proprietary ARCUS genome editing technology enables the production of highly specific nucleases that can insert, remove, and modify DNA at essentially any location in a complex genome.
Symbiomix Therapeutics, LLC is a biopharmaceutical company focused on developing innovative treatments for women's health infections, particularly bacterial vaginosis (BV). Founded in 2012 and headquartered in Newark, New Jersey, with additional offices in Baltimore, Maryland, and Hamden, Connecticut, the company specializes in the development of its lead product, Solosec (secnidazole), a next-generation 5-nitroimidazole antibiotic designed for a convenient one-dose treatment. This drug offers enhanced pharmacokinetic properties that improve efficacy and tolerability for patients. Symbiomix is supported by prominent healthcare venture capital firms and aims to address the unmet therapeutic needs in the field of gynecologic infections. Since October 2017, it has operated as a subsidiary of Lupin Inc.